Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: GlobeNewswire
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research. Long COVID continues to affect millions of Americans; according to Yale Medicine, approximately 20 million adults in the U.S. are living with Long COVID, a condition that not only impacts individual health but also carries major economic consequences by keeping people out of the workforce and contributing to significant productivity losses across the nation. Tevogen believes its investigational drug, TVGN 489, which has demonstrated promising results in a Proof-of-Concept clinical trial, could potentially play an important role in addressing this ongoing public health crisis. Ryan Saadi, M.D., M.P.H., Chief Executive Officer of Tevo
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]Yahoo! Finance
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-QGlobeNewswire
- Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVIDGlobeNewswire
- Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash BurnGlobeNewswire
TVGN
Sec Filings
- 11/14/25 - Form 424B3
- 11/14/25 - Form 10-Q
- 9/26/25 - Form 424B3
- TVGN's page on the SEC website